Patents by Inventor Anthony J. F. D'Apice

Anthony J. F. D'Apice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7201899
    Abstract: Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme ?-1,3 galactosyltransferase. The porcine gene encoding ?-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the ?-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the ?-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: April 10, 2007
    Assignees: BresaGen Limited, St. Vincent's Hospital
    Inventors: Anthony J. F. d′Apice, Martin J. Pearse, Allan J. Robins, Robert J. Crawford, Peter D. Rathjen
  • Patent number: 6849448
    Abstract: Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme ?-1,3 galactosyltransferase. The porcine gene encoding ?-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the ?-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the ?-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: February 1, 2005
    Assignee: BresaGen Limited
    Inventors: Anthony J. F. D'Apice, Martin J. Pearse, Allan J. Robins, Robert J. Crawford
  • Publication number: 20040171155
    Abstract: Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme &agr;-1,3 galactosyltransferase. The porcine gene encoding &agr;-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the &agr;-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the &agr;-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
    Type: Application
    Filed: January 21, 2004
    Publication date: September 2, 2004
    Applicants: BresaGen Limited, an Australia corporation, St. Vincent's Hospital and Anthony J. D'Apice of Australia
    Inventors: Anthony J.F. d'Apice, Martin J. Pearse, Allan J. Robins, Robert J. Crawford, Peter D. Rathjen
  • Patent number: 5849991
    Abstract: Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme .alpha.-1,3 galactosyltransferase. The porcine gene encoding .alpha.-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating ("knocking out") the .alpha.-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the .alpha.-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: December 15, 1998
    Assignees: Bresatch Limited, St. Vincent's Hospital
    Inventors: Anthony J. F. d'Apice, Martin J. Pearse, Allan J. Robins, Robert J. Crawford, Peter D. Rathjen